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Universidad de Navarra, Pamplona, Spain
Abstract
Immunotherapeutic monoclonal antibodies (mAbs) can be
defined as those that exert their functions by tampering with
immune system cell molecules, causing an enhancement of
antitumor immune responses. Some of these antibodies are
agonistic ligands for surface receptors involved in the activa-
tion of lymphocytes and/or antigen-presenting cells, whereas
others are antagonists of mechanisms that normally limit the
intensity of immune reactions. Several mAbs of this category
have been described to display in vivo antitumor activity in
mouse models. Only anti–CTLA-4 (CD152) mAb has entered
clinical trials, but the preclinical effects described for anti-
CD40, anti-CD137 (4-1BB), anti-CD102 (intercellular adhesion
molecule-2), and regulatory T cell-depleting mAbs should lead
to their prompt clinical development. Their use in combination
with immunizations against tumor antigens has been reported
to be endowed with synergistic properties. This new group of
antitumor agents holds promise for at least additive effects with
conventional therapies of cancer and deserves intensive trans-
lational research.
Introduction: Therapy of Malignant Diseases
with mAbs1
Some mAbs are therapeutic agents with progressive impact
in the treatment of a wide array of conditions. Since their
discovery in the late 1970s (1), it became clear that these
antibodies of defined specificity, and that could be produced in
high amounts, had potential for the management of various
diseases, including malignancies (2–4). In fact, cancer in its
different forms stood out as the most suitable target (5–7), given
that specific recognition of tumor-specific surface proteins was
thought to yield “magic bullets” that would selectively guide
effective mechanisms of cellular destruction to the malignant
cells.
The key property of antibodies to be used as therapeutic
tools is their behavior as high-avidity ligands to virtually any
protein or glycoprotein of the organism. Classically, antibodies
have been made immunizing rodents with the desired antigen
and fusing their activated splenic B lymphoblasts to myeloma
cell lines, resulting in clones of immortalized hybrid cells that
would continuously produce the antibody (1). Caveats in this
approach are that if the antigen is identical or very homologous
between the rodent species and humans, such “anti-self” anti-
bodies are difficult to obtain. This is important because active
sites in functional proteins are typically highly conserved. In
addition, rodent immunoglobulins have sequences that are rec-
ognized as strong antigens by the human immune system, thus
preventing repeated administration. Genetic engineering has
offered solutions to both problems, first by generating random
libraries for the antigen-binding site of the antibodies that could
be selected in vitro without self-tolerance bias (8). In addition,
molecular engineering has permitted extensive replacement with
human sequences, preserving only the antigen-binding site of
the mouse immunoglobulin. Thus, modified antibodies are
called humanized antibodies (9). Only recently, mouse strains
have been generated that have silenced endogenous immuno-
globulin genetic regions while having functional transgenic hu-
man immunoglobulin loci (10). Amazingly, those mice, when
immunized, produce entirely human antibodies, and, therefore,
completely human mAbs can be made from these mice by
conventional techniques (11). In general, pharmacokinetics of
antibodies are considered very favorable because they are pro-
tease resistant, stable in plasma, and, thus, generally endowed
with long half-lives.
Anticancer antibodies can be classified according to the
mechanism or mechanisms of action (Fig. 1) in the following
groups: (a) Malignant cell-destroying mAbs: the meaning is that
these antibodies bind tumor cells either specifically or selec-
tively, causing their death (12). The antibody biomolecule has
intrinsic functions that can mediate destruction of the tumor cell
(13), such as complement fixation, antibody-dependent cellular
cytotoxicity, and phagocytosis. In addition, artificial toxins or
Received 9/8/03; revised 9/25/03; accepted 10/6/03.
Grant support: Spanish Comision Interministerial de Ciencia y Tec-
nologia (SAF02/0373), Gobierno de Navarra (Departamento de Salud),
Fondo de Investigacio´n Sanitaria (Redes de centros de Investigacio´n
Cooperativa–RETICs C03/10 and C03/02 and BEFI Fellowship Pro-
gram) and a scholarship from Ministerio de Educacio´n y Cultura. M. B.
is a Leukemia and Lymphoma Scholar in Clinical Research.
The costs of publication of this article were defrayed in part by the
payment of page charges. This article must therefore be hereby marked
advertisement in accordance with 18 U.S.C. Section 1734 solely to
indicate this fact.
Requests for reprints: Ignacio Melero, MD, PhD, Facultad de Medi-
cina, C/Irunlarrea, 1, 31008 Pamplona, Spain. E-mail: imelero@unav.es.
1 The abbreviations used are: mAb, monoclonal antibody; APC, antigen-
presenting cell; DC, dendritic cell; GM-CSF, granulocyte macrophage
colony-stimulating factor; Treg, regulatory T cell(s); TNF, tumor ne-
crosis factor; NK, natural killer; IL, interleukin; ICAM, intercellular
adhesion molecule; TGF-, transforming growth factor ; VEGF,
vascular endothelial growth factor. CTLA, cytotoxic T lymphocyte
antigen; PD-1, programmed cell receptor-1, BTLA, B- and T-cell atten-
uator; DC-SIGN, dendritic cell-specific ICAM-3–grabbing nonintegrin.
5454 Vol. 9, 5454–5464, November 15, 2003 Clinical Cancer Research
 American Association for Cancer Research Copyright © 2003 
 on July 19, 2011clincancerres.aacrjournals.orgDownloaded from 
radiactive compounds can be coupled with the antibody to
enhance cellular destruction (12, 14–16). (b) mAbs that inter-
fere with signals transmitted from receptors for growth factors
(17, 18): the rationale is that cancer cells sometimes need the
constant signaling from mutated or nonmutated surface recep-
tors both for survival and/or progression in the cell cycle (19).
These antibodies block the signals required by tumor cells to
survive and thrive (20). (c) Antibodies inhibiting angiogenesis:
this subclass of mAbs targets vascular growth factors and their
receptors (17, 21, 22) or surface proteins selectively expressed
by proliferating endothelium (23, 24). Because malignancies
rely on continuous angiogenesis and vasculogenesis to progress
(19), these approaches have great potential. (d) mAbs that
enhance the cellular immune response against cancer: these
agents bind molecules on the surface of immune system cells.
What they do is either provide activating signals to lymphocytes
and APCs or block the action of receptors that normally down-
regulate the immune response. Here, we focus on this last
category (Fig. 1).
The Complex Set of Cellular and Molecular
Mechanisms That Amplify, Inhibit, or Shape the
Cellular Immune Response
The orchestration of an efficacious, cytotoxic immune re-
sponse is the result of a complex interplay of many cell types
that are controlled in their functions by signals received
through surface receptors (25). Those receptors detect antigens,
microbe-denoting patterns, or are involved in intercellular com-
munication by cytokines or cell-to-cell contact (25).
Normally, an immunogenic antigen is picked up at periph-
eral inflamed tissues by DCs (26, 27). Those DCs are deployed
and recruited to these tissues and are specialized in uptaking,
processing, and presenting foreign antigenic substances in MHC
class I and II molecules, as well as in other antigen-presenting
molecules such as CD1 (28). Besides, they sense the environ-
ment for cell damage (29), microbe patterns (30), and proin-
flammatory cytokines. If those stimuli are detected by the cor-
responding receptors, DCs migrate avidly to lymphoid tissue
and up-regulate soluble and membrane-attached glycoproteins
Fig. 1 Graphic representation of the different mechanisms of action postulated for immunotherapeutic mAbs. In several instances, a single mAb can
operate through more than one general mechanism of action, as indicated in the legend on the right side of the graph.
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that are necessary to productively activate antigen-recognizing
T cells.
Once in lymphoid tissue, a bidirectional dialogue between
APCs and lymphocytes takes place with the participation of
many receptor-ligand pairs in opposed cell surfaces, cytokines,
and chemokine gradients.
As a result of early activation of resting (naive or memory)
lymphocytes, those cells express surface proteins that were
undetectable before, called lymphocyte activation antigens.
Those surface molecules are thereafter ready to receive infor-
mation by their corresponding ligand or ligands.
The overall result of such many interactions is a bursting
clonal expansion of responding T cells acquiring effector func-
tions that are capable of destroying and clearing antigen-bearing
cells.
DCs also receive activation signals by T-helper cells
mainly, but not only, through the CD40L/CD40 pair. The con-
sequence of this phenomenon is induction and/or maintenance
of the active (proimmune or mature) state of DCs (31).
Most activated T cells will eventually die through pro-
grammed cell death pathways that regulate the number of
antigen-specific lymphocytes (32). Some surface receptors are
involved in triggering this apoptotic event, whereas other recep-
tors signal to prevent or delay such an outcome (33, 34).
During the close contact of T cell/DC membranes, various
types of molecules play a role in the so-called immunological
synapse (35–38): (a) antigen receptor and antigen-presenting
molecules; (b) adhesion molecules that hold the cells together in
a regulated fashion; (c) chemokines that attract the leukocyte
populations to the rendezvous tissue locations; (d) costimulatory
receptors that promote division and acquisition of effector func-
tions, supplying complementary signals to those arising from
antigen receptors; (e) inhibitory receptors that down-regulate the
size and potency of immune response; and (f) soluble activating
or inhibiting cytokines.
Besides, there are T cells that are known to be specialized
in regulating the extent of cytolytic responses, either by pro-
moting it or by inhibiting it. T-helper cells are those that provide
cytokines and activation of APCs for optimal CTL generation
(39–41), whereas Treg are specialized in quenching early im-
mune responses or in maintaining peripheral tolerance to au-
toantigens (42–45).
The principle of immunotherapeutic mAbs is that all those
types of receptors can be potentially blocked or activated in vivo
by mAbs and that specific subsets of Treg can be eliminated by
specifically depleting antibodies (Fig. 1).
Anti–CTLA-4 (CD152) Antibodies
A humanized antibody against CTLA-4 was the first to
reach clinical trials (46, 47). CTLA-4 is a surface protein that
belongs to the CD28 family of receptors (48, 49). In fact,
CTLA-4 shares its ligands with that molecule (50). However, in
contrast to the costimulatory activity of CD28 (51), CTLA-4
ignites signals that inhibit cell cycle progression and cytokine
secretion (52). CTLA-4 is expressed only by activated T cells
and regulatory CD4 CD25 T cells (42, 53).
Knowledge of its key functional role as a brake system for
T cells comes from observations in CTLA-4/ mice that
develop a lethal autoimmune syndrome with infiltration of mul-
tiple organs by activated lymphocytes (54, 55). The mechanism
is the lack of control of CD28-mediated costimulation of T cells
(56), and probably on dysregulation in the Treg cell activity, as
suggested by the control of CTLA-4/ T cells on adoptive
transfer into mice with CTLA-4/ T cells (57).
CTLA-4 is retained in intracellular compartments (58) and
directed to the cell surface area in which a productive interaction
with a DC is taking place (59). The cytoplasmic tail of CTLA-4
recruits Tyr and Ser/Thr phosphatases (60, 61) that attenuate
signals through activating receptors.
CTLA-4 has binding activity both for CD80 (B7-1) and
CD86 (B7-2). The affinity of its interactions toward those re-
ceptors is much higher than that displayed by CD28 and, there-
fore, would compete with advantage for the ligands (38).
Anti–CTLA-4 antibodies can block the function of the
molecule in vitro, even as Fab monovalent fragments (62, 63).
In vivo, systemic treatment of mice with transplantable immu-
nogenic colon carcinoma cells with anti–CTLA-4 mAb caused
complete tumor regression of established tumors through an
immune response found to be critically dependent on the activ-
ity of CTLs (64). The antitumor effect was also remarkable
against spontaneous prostate carcinomas arising in mice trans-
genic for the SV40-T antigen under a tissue-restricted promoter
(65). The effects of anti–CTLA-4 mAb were greatly potentiated
by combining it with treatments based on vaccination with
autologous tumor cells transfected to express GM-CSF (66, 67).
GM-CSF transfection was previously known to favor immuni-
zation against tumor antigens by means of local recruitment and
differentiation of bone marrow-derived APCs such as DCs
(68–70). Other studies have confirmed the synergy between
vaccination and anti-CTLA-4 mAb treatment (71).
A humanized mAb (MDX.010.Medarex) has entered clin-
ical trials as a single agent in patients suffering from metastatic
melanoma and ovarian cancer who are refractory to conven-
tional treatments (46). Some of those patients had previously
undergone vaccination with allogeneic melanoma cell lines se-
creting GM-CSF. CTLA-4 mAb induced tumor infiltration by
mononuclear and polymorphonuclear leukocytes that, in some
cases, led to a clinical response with a late onset after the single
administration of the antibody. Indeed, doses in this study
featured only a single dose of 3 mg/kg. In one case, the patient
developed acute inflammation and swelling of a previously
unnoticed central nervous system melanoma metastasis, which
caused serious neurological complications and, ultimately, the
death of the patient.
Other clinical trials are ongoing, and it has been recently
reported that there is therapeutic synergy between vaccination
with a peptidic antigen expressed by melanomas (gp100) and
repeated, weekly doses of anti–CTLA-4 mAb (47). In these
patients, events of severe autoimmunity beyond vitiligo (such as
inflammatory bowel disease, hypophysitis, and eczema) have
been observed, but they have been reversible in every case.
Those trials stress the following points: (a) the effect of many
among these novel, immunity-promoting mAbs can be potenti-
ated by specific immunizations; and (b) autoimmunity is a real
risk and possibly a price to pay. Interestingly, the two long-
lasting complete responders from a total of 14 patients endured
the most severe autoimmune adverse events: one case with
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hypophysitis causing panhypopituitarism and the other with
severe dermatitis (47).
Other molecules may exert a similar function. One poten-
tial target is the PD-1 molecule also expressed by activated T
cells (72). PD-1/ mice also develop autoimmunity, but less
intense than CTLA-4/ mice (72, 73). PD-1 also binds B7
family members B7-H1 (PDL1) and B7-DC (PDL2), although
the exact function of these molecules is unclear. The suspected
existence of yet unidentified alternative ligands defies the de-
scription of a more a clear-cut picture. To the best of our
knowledge, PD-1-blocking mAbs have not been tried in mouse
tumor models yet. B7-H1 is expressed by many mouse and
human tumor cell types and is known to induce T-cell apoptosis
(74). Indeed, the blocking of B7-H1 with mAbs has shown
antitumor effects in those cases (74). In addition, B7-H1 expres-
sion is induced on intratumor DCs, as described in DCs found in
malignant ascites, suggesting that this molecule greatly hampers
DC T-cell-stimulating properties (75). Anti–B7-H1-blocking
mAbs are definitive candidates for clinical impact in the future
(76).
Only very recently, BTLA has been described as a relative
of CTLA-4 that is expressed by activated T and B cells (77). It
apparently binds the previously orphan B7 member B7x (B7-
H4) and transmits inhibitory signals (78, 79) by Src homology
domain-2 containing tyrosine phosphatase recruitment to its
phosphorylated cytoplasmic tail (77). Interference of BTLA
function in tumor immunotherapy is an obvious next step.
BTLA/ mice do not develop spontaneous autoimmunity but
are more prone to develop severe experimental allergic enceph-
alitis than control littermates (77). Multiple, simultaneous, or
sequential blockade of all those inhibitory pathways involving
B7 family members is a direction worth taking to enhance
therapeutic effects in the future.
Anti–4-1BB (CD137)
4-1BB (CD137) is a surface glycoprotein that belongs to
the TNF receptor family. It is expressed by activated, but not
resting, T and NK cells (80, 81). Recently, its expression on
DCs has been reported also (82). There is only one known
ligand for this molecule, named 4-1BBL, that belongs to the
TNF family and is expressed by APCs such as macrophages,
activated B cells, and activated DCs (83).
Ligation of 4-1BB in vitro by antibodies or natural ligands
provides costimulation for lymphocyte proliferation and cyto-
kine secretion (84–86). Costimulation by anti–4-1BB mAb is
largely independent of that provided by CD28 (87), although
CD28 ligation promotes 4-1BB surface expression (88).
4-1BB/ and 4-1BBL/ mice have mild immune defects in
generation of CTLs against T-helper-dependent antigens (89,
90). These observations indicate the existence of other redun-
dant pathways that possibly take over the function in the knock-
out mice.
4-1BB activates several intracellular signaling pathways
that include: TRAF-2, nuclear factor B, mitogen-activated
protein kinases, BCL-xL, Bfl-1, and others (87, 91, 92). How-
ever, the exact signal or subset of signals responsible for its
unique costimulatory properties remains elusive.
Treatment of mice bearing established transplanted tumors
with anti–4-1BB mAbs causes tumor regression even in tumor
models considered to be poorly immunogenic (93). The effect
depends on the activation of CTLs and is dependent on CD4
T-helper cells in a tumor model-dependent fashion (93, 94). NK
cells expressing 4-1BB are also important to trigger the thera-
peutic effects by means of their cytokine secretion activity
rather than through direct cytotoxicity (81, 95). Normal function
of IFN is absolutely required for the therapeutic effect, mainly
to mediate the homing of effector T cells to tumor tissue (96).
Antibodies against 4-1BB also greatly potentiate the effect of
adoptive therapy with preactivated CD8 T cells specific for
tumor antigens (97–99). Some of the effects are clearly depend-
ent on the ability of anti–4-1BB mAb to prevent programmed
cell death in lymphocytes, thus extending their operative life
(98, 100).
Transfection of tumors with the cDNA encoding for
4-1BBL also augments their immunogenicity (88, 101). How-
ever, such a treatment is less potent than the one mediated by
artificial ligation of 4-1BB with mAbs (88, 102). This observa-
tion can be attributable to either different binding avidities or to
the systemic, rather than local, distribution of the mAb. The
issue of avidity is further supported by results showing that
tumor cell transfection with a membrane-attached scFv form of
an anti–4-1BB mAb results in a very high tumor immunoge-
nicity (103). In these experiments, a crucial role for NK cells in
the antitumor effect was also found.
Treatment with anti–4-1BB mAb synergizes with transfec-
tion of tumors to express IL-12. In particular, such a combined
treatment eradicated advanced experimental colon cancer me-
tastasis in mice (104, 105). Moreover, the combination of anti–
4-1BB mAb with vaccination using chemically defined peptides
encoding for tumor antigens was very efficacious in a synergis-
tic fashion (106). It seems that anti–4-1BB mAbs can up-
regulate a formerly weak, but present, immune response. How-
ever, they fail to initiate any immune response from zero.
In case there is a complete ignorance by the immune
system of the relevant tumor antigens, vaccinations are probably
required. Among other reasons, antigen stimulation is necessary
to induce 4-1BB expression on specific T cells. Once antigen
ignorance is broken, anti–4-1BB mAb can greatly promote
antitumor immunity (106). Recently, we have found that potent
synergistic effects are elicited by anti–4-1BB mAb combined
with intratumoral injections of cultured DCs engineered to pro-
duce IL-12.2 Such DCs cross-prime tumor antigens and induce
an immune response that can be amplified by anti–4-1BB mAb.
Antibodies against another member of the TNF receptor
family, named OX-40 (CD134), have antitumor effect, although
much less intense. This fact has been attributed to the preferen-
tial costimulation of CD4 lymphocytes by anti-OX-40, a sit-
uation that mirrors the preferential costimulation of CD8 T
cells by anti–4-1BB mAb (107).
In addition, treatment with anti–4-1BB mAb has inhibitory
activity on some pathogenic functions mediated by T-helper
2 I. Tirapu, Improving efficacy of interleukin-12–transfected dendritic-
cells injected into murine colon cancer with anti-CD137 monoclonal
antibodies and alloantigens, submitted for publication.
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cells by yet undefined mechanisms (108). These T-helper-inhib-
itory effects of anti–4-1BB mAb clearly ameliorate experimen-
tal autoimmunity conditions, such as mouse models of lupus
(109, 110) and experimental allergic encephalitis models (111).
The precise role of the in vivo effects of anti–4-1BB mAb on
CD4 T cells in tumor immunotherapy remains to be elucidated
and might involve Treg cells. Costimulation via 4-1BB has also
been implicated in shaping the T-helper response toward a Th1
pattern of cytokine secretion (112).
A humanized anti–4-1BB mAb has been tested in nonhu-
man primates without toxicity and with interesting observations
of inhibition of T cell-dependent antibody responses in these
animals (113). Clinical development and eventual trials with
mAbs of this specificity are planned in various institutions,
including ours.
Anti-CD40
CD40 is a TNF receptor family member that plays a crucial
role in shaping both the cellular and the humoral immune
response (114). It is chiefly expressed on B cells, DCs, and
macrophages. Its specific ligand (CD40L) is expressed by acti-
vated T-helper cells in a highly restricted fashion (114). CD40L
genetic deficiency in mice and humans causes both humoral and
cellular immunodeficiency attributable to both failure of immu-
noglobulin class switch in B cells and lack of DC activation to
prime T-cell responses (115). Therefore, CD40 is a key mole-
cule in the instructive activity of T-helper cells (116). Recently,
it has been found that CD40 is also expressed by CD8 T cells
and plays a key role in the activation of memory but not naive
CTL precursors (117).
Treatment of mice bearing B-cell malignancies with an
antibody against CD40 leads to complete cure in many cases
(118). The mechanism of action seems to be double. On one
hand, the antibody stimulates an antitumor CTL-mediated im-
mune response. In contrast, direct binding of CD40 on the
surface of lymphoma and myeloma cells seems to kill tumor
cells and might also enhance the antigen-presenting functions of
these neoplastic B cells (118, 119). It should be also mentioned
that tumor cell transfection with CD40L also increases immu-
nogenecity and exerts therapeutic activity (120–122).
The property of expressing surface CD40 is not limited to
hematological malignancies but extends to many other types of
tumors such as carcinomas (123). This explains the reason for
strategies based on targeting CD40 with immunotoxins (mAb-
toxin conjugates) that are currently being explored with some
encouraging results (124).
Nonetheless, such an antitumor activity can be found even
in tumors in which CD40 expression is completely undetectable
(125). Even more, the best therapeutic effects are achieved if
anti-CD40 antibodies are combined with vaccinations with an-
tigenic peptides shared by tumor cells (125). The mechanism
involves the general maturation of endogenous DCs that evokes
productive proliferation and effector differentiation of T cells. In
this study, an important warning call has been made, because
mice treated i.v. with anti-CD40 antibodies may experience a
shock syndrome that resembles endotoxin-caused shock (125).
Importantly, though, the same antibody doses given inside s.c.
malignant nodules achieves identical therapeutic activity with-
out the lethal adverse events (125).
Clinical grade, antihuman CD40 is about entering Phase I
clinical trials for different types of lymphoma in Southamptom,
United Kingdom. The synergistic effects of anti-CD40 mAb
with radiotherapy observed in preclinical lymphoma models are
to be developed in the clinic as well (126). These combined
effects might have something to do with the reported opsonizing
activity of antitumor antibodies that favors cross-presentation of
tumor antigens by DCs (127).
Anti–ICAM-2 (CD102)
ICAM-2, a member of the immunoglobulin superfamily
encompasing two immunoglobulin domains, was originally de-
scribed as a counterreceptor for the leukocyte integrin leukocyte
function antigen-1 (128, 129). Its expression is restricted to
endothelial cells and lymphocytes (130). The surface expression
on lymphocytes is up-regulated on activation from low basal
levels and, importantly, many malignancies derived from both T
and B lymphocytes are ICAM-2 positive. Recent studies have
established that mannose-rich carbohydrate structures attached
to ICAM-2 interact with the DC-specific lectin DC-SIGN
(CD209) (131, 132), playing, therefore, a potentially important
role both in DC-T-cell interactions and DC trafficking through
endothelial barriers.
Administration of anti-ICAM-2-specific mAbs to mice
bearing ICAM-2-negative established tumors induces complete
regressions through a mechanism dependent on CD8 T cells,
which correlates with induction of tumor-specific CTLs (133). It
has been described recently that, on ligation, human ICAM-2
ignites a signaling pathway that inhibits programmed cell death
(134). Those signals involve intracytoplasmic transient interac-
tions of ICAM-2 with ezrin as well as a series of downstream
events that interfere with the mitochondria apoptosis pathway
through inositol-3-phosphate kinase and Akt (protein kinase B)
activation (134). In addition, binding of immunotherapeutic
mAbs to ICAM-2 can enhance its adhesiveness to its cognate
ligand DC-SIGN (133), although the real impact of this adhe-
sion phenomenon on the antitumor effects remains elusive.
Additional research in the mouse tumor models has demon-
strated that immunotherapy with anti-ICAM-2 mAbs promoted
the survival of activated T lymphocytes that recognize tumor
antigens both in vivo and in vitro (135). As a result of this
mechanism of action, these therapeutic antibodies enhance the
antitumor activity of immunization procedures against tumor
antigens, such as the in vivo gene transfer of IL-12 to malignant
cells (135). As a consequence, two important experimental
directions are being taken in this field to: (a) elucidate the
physiological functions of ICAM-2 as a player in immunolog-
ical synapses as well as the control on T-cell survival; and (b)
further exploit ICAM-2 artificial ligation with antibodies as a
therapeutic tool to enhance T-cell immunity against tumors and
infectious agents.
Importantly, potential toxicity problems have been identi-
fied with regard to a cytokine storm syndrome on combination
of anti–ICAM-2 mAb with both IL-12 gene therapy and with
adoptive transfer of T cells (135). Nonetheless, two interesting
pieces of information came out in those studies: (a) a nontoxic
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therapeutic window of doses can be found; and (b) in vivo
blockade of IFN activity, once the tumors had regressed, was
capable of preventing the mentioned lethal toxicity.
Anti–ICAM-2 and anti–4-1BB mAbs are agents that act, at
least partially, on the contraction phase of the immune response
that physiologically follows clonal expansion (34). Interfering
with activation-induced cell death renders a more numerous
army of tumor-specific T lymphocytes that can deal with greater
tumor burdens but can also lead to a dangerously higher output
of cytokines.
Possible antiangiogenic mechanisms were searched for,
because ICAM-2 is expressed on vascular cells with some
degree of selectivity in mouse tumor vessels. Although experi-
ments have failed to show a decrease in vascularization of
implanted matrigel plugs. Some delay in nude mice was found
in the growth of transplanted angiomas. These results indicate
that an antiangiogenic component in the overall antitumor effect
cannot be ruled out (133).
Depletion or Inactivation of Regulatory T Cells
Silence to endogenous antigens is enforced by thymic
mechanisms that delete autoreactive clones (136). In addition,
there exist peripheral mechanisms that maintain unresponsive-
ness to self-antigens. In particular, a population of CD4
CD25 T cells has been identified as a key mediator of these
functions (42, 45, 137). Either their depletion, or their genetic
absence caused by lack of Fox-P3 (138–140), shows their
importance at preventing and ameliorating autoimmune condi-
tions (141). In fact, Treg-adoptive transfer prevents or treats
experimental autoimmunity in various models (142). These Treg
cells constitutively express CTLA-4 (42) and the orphan TNF
receptor family member GITR (glucocorticoid-induced TNF
receptor family-related gene; Refs. 143 and 144). They also
selectively express the Fox-P3 transcription factor (138–140).
Transfection of this gene is sufficient to induce thymocytes to
differenciate into Treg cells (140). Treg cells inhibit prolifera-
tion and activation of effector T lymphocytes through actions
performed in close membrane contact-based functions (42, 45,
137).
Depletion of Treg cells with anti-CD25 mAbs exerts anti-
tumor effects (145) by permitting the activation of antitumor
CD8 and CD4 effector T cells (145, 146). At least part of the
antitumor effect is mediated by CD4 effector T lymphocytes
that promiscuously recognize various unrelated tumor cell lines
and secrete IFN.4 The antitumor activity of those CD4 cells
was found to be largely dependent on the ability of IFN to
inhibit tumor vascularization. The combination of CD25 deplet-
ing mAb, anti-CTLA-4 mAb, and vaccination with a GM-CSF-
transfected variant of a poorly immunogenic melanoma causes
synergistic antitumor effects (71).
Anti-GITR antibodies have been reported to functionally
interfere with Treg functions (143), thus defining a potential
target for this kind of immunotherapeutic agent in cancer treat-
ment. Translational research on this idea has already started.
Because resting Treg cells express CD25, which is the 
chain of the high-affinity receptor of IL-2, an IL-2-toxin chi-
meric protein that had been developed for cutaneous lymphoma
treatment is being used as a Treg-depleting agent (147, 148). To
achieve depletion, antihuman CD25 mAbs are also available for
development (149).
Other T cells with regulatory functions exist, such as CD4
cells (called Tr1 cells), that secrete IL-10 and TGF- (44, 150).
Interference with their functions has not been reported to en-
hance tumor immunity but it might be important in some in-
stances.
Interference with Cytokines That Down-Regulate
the Immune Response
Certain soluble factors are known to depress the cellular
immune response. TGF- and its receptors are the best known
(151, 152). TGF- inhibits T-cell activation at many levels,
including lymphocyte proliferation and the function of APCs
(153). Tumors frequently produce high amounts of this factor,
and there is mouse genetic evidence that TGF- receptors on
lymphocytes are involved in the failure of immune surveillance
against tumors (154). Other soluble factors such as VEGFs
(155–157) and IL-10 (158–160) are endowed with similar prop-
erties. Interference of the function of these mediators can be
achieved with blocking antibodies, decoy receptors, peptides,
and other means.
The T-cell activation antigen CD69 has been implicated
recently in the control of TGF- secretion (161). CD69 exerts a
“brake” function on the immune response. CD69/ mice
mount stronger responses against certain experimental tumors.
Moreover, in vivo down-modulation of CD69 from the surface
of lymphocytes with specific mAbs increase antitumor immu-
nity in some models (161). It remains to be seen whether
interference with TGF- through CD69 would be effective
under conditions in which tumor cells were producing high
amounts of this soluble mediator.
In the case of anti-VEGF (162) and anti-VEGF receptor
(22) humanized antibodies that are being clinically tested, future
experimentation should evaluate the real effect of interfering
VEGF on the antitumor immune response.
Conclusions: The Road Map to Clinical
Development
The road map to clinical development includes: (a) Immu-
notherapeutic mAbs emerge as a new family of agents with
potential in cancer treatment. Among their virtues, the ability to
synergize with other more conventional therapies stands out. (b)
Augmentation of immune responses is also a goal in other
conditions such as chronic viral infections (i.e., chronic hepati-
tis, herpes virus chronic, or latent infections, and so on). There-
fore, other indications for these antibodies might lie ahead. (c)
Several specificities of mAbs with these properties have been
examined in murine models of cancer, but many other molecules
of the immune system might still hold exploitable secrets for
3 N. Casares, L. Arribillaga, P. Sarobe, J. Dotor, A. Lopez-Diaz De
Cerio, I. Melero, J. Prieto, F. Borras-Cuesta, and J. J. Lasarte. CD4/
CD25 regulatory cells inhibit activation of tumor-primed CD4 T
cells with IFN-dependent antiangiogenic activity, as well as long-
lasting tumor immunity elicited by peptide vaccination. J. Immunol., in
press.
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mAbs. Currently, the clinical experience involves only early
trials with anti–CTLA-4 mAbs, indicating that this field is at its
infancy. (d) Autoimmunity is a clear danger of immunotherapy,
and it is becoming more evident when relevant efficacy results
are being achieved (162). Learning how to manage such com-
plications and assessing the balance of adverse versus beneficial
immunity will be an important and difficult clinical topic in the
near future of immunotherapy. (e) If immunotherapy of cancer
were a car, a formula to its racing success might be (163, 164)
to start the engine (immunization/vaccination), jump on the
accelerators (exaggerate costimulation), and release the brakes
(tamper with the mechanisms that enforce immune tolerance
and keep ongoing immune responses under control). mAbs can
be very useful tools, particularly for the last two steps. Mutual
potentiation by combinations of agents acting at each step is
gaining experimental support both in preclinical and clinical
settings. The more regulatory checkpoints are tampered with,
the more the risk for unwanted inflammation will be increased.
Skillful and wary clinical steering will be much needed. (f)
Clinical development requires resources and expertise that in-
volve bioprocessing, GMP manufacturing, toxicology, regula-
tory affairs, both scientists and clinicians directly involved in
translational research, experts in complex intellectual property
issues, and so on. Those resources are normally only available to
industry. Those companies already in business with humanized
mAbs have the advantage and only need to recruit or outsource
expertise in monitoring antitumor immune responses. Cellular
immunology and immunohistochemistry tests are to be used as
surrogate end points for clinical trials. Industrial liaisons are a
must, and the current state of the field should attract investment
for development of at least some of these novel therapeutic
options. The prediction of which of these will finally pay off is
clearly a difficult forecast, but there exists profound reasons for
optimism in many of them.
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